Ignite Creation Date:
2025-12-24 @ 1:20 PM
Ignite Modification Date:
2026-01-03 @ 9:06 AM
Study NCT ID:
NCT03491995
Status:
UNKNOWN
Last Update Posted:
2018-04-10
First Post:
2018-04-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Unique Regimen for Treatment of Helicobacter Pylori Infection
Sponsor:
Sherief Abd-Elsalam
Organization:
Study Overview
Official Title:
A Unique Quadruple Regimen for of Helicobacter Pylori
Status:
UNKNOWN
Status Verified Date:
2018-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The triple treatment including Proton pump inhibitor (PPI) -clarithromycin and amoxicillin or metronidazole was proposed 30 years ago at the first Maastricht conference to treat helicobacter pylori (H. pylori) infection and since that time, it has become the universal and standard treatment for helicobacter pylori.
However, the efficacy of this triple regimen has been seriously challenged, and they are gradually becoming ineffective
However, the efficacy of this triple regimen has been seriously challenged, and they are gradually becoming ineffective
Detailed Description:
Growing rates of treatment failure are observed worldwide and the eradication rate of triple therapy has declined over the past few decades. Helicobacter pylori infection has become increasingly resistant to traditional first line treatment regimens because of emerging antibiotic resistance coupled with poor patient compliance with completing the treatment course that decrease H. pylori eradication rates .So there is a considerable interest in evaluating new antibiotic combinations and regimens .
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: